ArticleImmuno-oncology technology2026
Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures.
Article in Immuno-oncology technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibition (ICI) provides durable benefit across several cancers but carries a substantial risk of immune-related adverse events (irAEs). Management relies primarily on corticosteroids, yet responses are variable and difficult to predict. In this observational study, we explored whether early immune phenotypes in fresh whole blood reflect organ-specific irAEs and corticosteroid responsiveness. Materials and methods: We prospectively enrolled patients receiving ICI who developed grade 2-4 colitis, hepatitis, or nephritis. Peripheral blood was collected at irAE onset (T0) and during early management (T1). Immune profiling was carried out on fresh blood by flow cytometry and unsupervised clustering. Results: Twenty-seven patients were included (colitis Conclusions: In this explorative study, fresh-blood immunophenotyping suggested associations between irAE type, early immune signatures, and corticosteroid response. These hypothesis-generating and preliminary findings support further research into a more individualized immune-guided approach to irAE management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.